

Alan Menter

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6852112/alan-menter-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

197
papers

16,548
citations

57
h-index

128
g-index

208
ext. papers

18,850
ext. citations

5.7
avg, IF

6.28
L-index

#	Paper	IF	Citations
197	Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options. <i>Dermatology and Therapy</i> , 2021 , 11, 1917-1929	4	5
196	AB0544 EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND reSURFACE 2. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1304.2-1305	2.4	
195	Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferences. <i>Dermatologic Therapy</i> , 2021 , 34, e14486	2.2	1
194	Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 432-470	4.5	46
193	Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 87-96	5.4	2
192	A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm. <i>Dermatology and Therapy</i> , 2021 , 11, 1851-1860	4	1
191	Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2409-2414 ¹	4.6	1
190	Penile calciphylaxis with extragenital gangrene. <i>Baylor University Medical Center Proceedings</i> , 2021 , 34, 416-418	0.6	
189	Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. <i>Dermatology and Therapy</i> , 2021 , 11, 385-400	4	7
188	Normocomplementemic urticarial vasculitis in a young female with persistent joint pain. <i>International Journal of Dermatology</i> , 2021 ,	1.7	
187	Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics. <i>Dermatology and Therapy</i> , 2020 , 10, 615-621	4	2
186	Diffuse dermal angiomatosis of the breast. <i>Baylor University Medical Center Proceedings</i> , 2020 , 33, 273-275	2	
185	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1445-1486	4.5	79
184	A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). <i>Journal of Investigative Dermatology</i> , 2020 , 140, 1784-1793 ²	4.3	36
183	A Quaternary Classifier for the Clinical Evaluation of Pigmented Skin Lesions 2020 ,		1
182	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 161-201	4.5	63
181	Topical dermal steroid-induced retinopathy. <i>JAAD Case Reports</i> , 2020 , 6, 868-870	1.4	1

180	A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment of Moderate-to-Severe Psoriasis. <i>Dermatology and Therapy</i> , 2020 , 10, 1121-1135	4	1
179	Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA B: Post-Hoc Analysis From Three Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020 , 10, 1111-1120	4	2
178	Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 519-522	4.5	9
177	Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e21-e24	4.6	2
176	IL-4R Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 191-202.e7	4.3	57
175	Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 763-768	2.8	4
174	Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). <i>British Journal of Dermatology</i> , 2020 , 183, 1037-1048	4	11
173	Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 863-871	7.1	19
172	Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2019 , 12, 249-253	2.9	2
171	Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI). <i>Journal of Medical Economics</i> , 2019 , 22, 936-944	2.4	3
170	Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. <i>British Journal of Dermatology</i> , 2019 , 181, 88-95	4	42
169	Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 923-930	4.5	5
168	Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines. <i>Transplant International</i> , 2019 , 32, 1268-1276	3	12
167	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1029-1072	4.5	296
166	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1073-1113	4.5	145
165	Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 155-172	11.5	246
164	Anti-IL17 therapies for psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 45-54	5.4	40
163	Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. <i>Therapeutic Advances in Chronic Disease</i> , 2018 , 9, 5-21	4.9	83

162	Prevalence of genital psoriasis in patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 754-760	2.8	17
161	A congenital naevus in a blaschkoid distribution. <i>Clinical and Experimental Dermatology</i> , 2018 , 43, 216-2188		
160	Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 88-101	6.1	41
159	No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2018 , 178, e105-e107	4	9
158	Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 2126-2133	4.6	10
157	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. <i>British Journal of Dermatology</i> , 2018 , 179, 844-852	4	59
156	Symptomatic hypercalcemia and scarring alopecia as presenting features of sarcoidosis. <i>Baylor University Medical Center Proceedings</i> , 2018 , 31, 224-226	0.6	2
155	Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 70-80	4.5	51
154	The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 1-19	5.1	15
153	Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 3879-3883	4.4	31
152	Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. <i>Circulation: Cardiovascular Imaging</i> , 2018 , 11, e007394	3.9	81
151	Ethical dilemma in missed melanoma: What to tell the patient and other providers. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 365-367	4.5	
150	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. <i>American Journal of Clinical Dermatology</i> , 2017 , 18, 405-411	7.1	16
149	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2017 , 376, 1551-1560	59.2	306
148	Adalimumab in paediatric psoriasis. <i>Lancet, The</i> , 2017 , 390, 5-6	40	0
147	Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, e544-e547	4.6	1
146	Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1686-1692	4.6	42
145	Quality of life instruments in psoriasis clinical trials. <i>British Journal of Dermatology</i> , 2017 , 176, 563	4	2

144	Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. <i>Dermatology and Therapy</i> , 2017 , 7, 365-381	4	30
143	A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis. <i>Immunotherapy</i> , 2017 , 9, 963-978	3.8	5
142	Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature. <i>Therapeutic Delivery</i> , 2017 , 8, 737-746	3.8	15
141	Multifactorial Diseases with Immunological Involvement 2017 , 221-258		
140	Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies. <i>Skinmed</i> , 2017 , 15, 119-124	0.2	19
139	Patient-relevant needs and treatment goals in nail psoriasis. <i>Quality of Life Research</i> , 2016 , 25, 1179-88	3.7	11
138	Comparison of Coronary Artery Calcium Scores Between Patients With Psoriasis and Type 2 Diabetes. <i>JAMA Dermatology</i> , 2016 , 152, 1244-1253	5.1	39
137	A novel classification system for dysplastic nevus and malignant melanoma 2016 ,		2
136	Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 1148-58	4.6	162
135	Image Gallery: Cutaneous T-cell lymphoma mimicking a gyrate erythema. <i>British Journal of Dermatology</i> , 2016 , 174, e42	4	
134	CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohorts. <i>British Journal of Dermatology</i> , 2016 , 174, 330-7	4	24
133	Palmoplantar pustular psoriasis unresponsive to the interleukin-1 antagonist canakinumab. <i>Clinical and Experimental Dermatology</i> , 2016 , 41, 324-6	1.8	11
132	Translating psoriasis guidelines into practice: Important gaps revealed. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 544-51	4.5	3
131	A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2016 , 27, 332-8	2.8	48
130	The spectrum of nephrocutaneous diseases and associations: Genetic causes of nephrocutaneous disease. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 231-44; quiz 245-6	4.5	4
129	The spectrum of nephrocutaneous diseases and associations: Inflammatory and medication-related nephrocutaneous associations. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 247-70; quiz 271-2	4.5	4
128	A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. <i>Dermatology and Therapy</i> , 2016 , 6, 1-12	4	92
127	Recurrent lumbosacral herpes simplex virus infection. <i>Baylor University Medical Center Proceedings</i> , 2016 , 29, 48-9	0.6	2

126	Developing more open and equitable relationships with industry to improve advancements in clinical research in dermatology. <i>British Journal of Dermatology</i> , 2016 , 174, 1365-9	4	2
125	Pustular psoriasis eruption with dabrafenib, a BRAF inhibitor. <i>Journal of Dermatological Treatment</i> , 2016 , 27, 418-21	2.8	5
124	Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies. <i>Dermatology and Therapy</i> , 2016 , 6, 639-647	4	12
123	A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 1337-1344	5.9	12
122	Discordance between physician assessment of psoriasis and patient self-assessment: the importance of itch. <i>British Journal of Dermatology</i> , 2016 , 175, 19-20	4	4
121	Psoriasis and psoriatic arthritis overview. <i>American Journal of Managed Care</i> , 2016 , 22, s216-24	2.1	13
120	Psoriasis and psoriatic arthritis treatment. <i>American Journal of Managed Care</i> , 2016 , 22, s225-37	2.1	8
119	Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 1763-70	4.6	54
118	Central obesity and high blood pressure in pediatric patients with atopic dermatitis. <i>JAMA Dermatology</i> , 2015 , 151, 144-52	5.1	61
117	Successful treatment of generalized granuloma annulare with adalimumab. <i>Clinical and Experimental Dermatology</i> , 2015 , 40, 537-9	1.8	5
116	Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 410-9.e6	4.5	49
115	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. <i>Lancet, The</i> , 2015 , 386, 541-51 ⁴⁰		57 ⁶
114	Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 978-83	4.5	103
113	Nodular fasciitis of the lip mucosa: a rare but clinically important entity. <i>Clinical and Experimental Dermatology</i> , 2015 , 40, 408-12	1.8	8
112	Phototherapy in dermatology: A call for action. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 1078-80	4.5	39
111	Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 136, 116-124.e7	11.5	182
110	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015 , 373, 1318-28	59.2	53 ⁰
109	Reporting of MABp1 for the Treatment of Psoriasis. <i>JAMA Dermatology</i> , 2015 , 151, 1143-4	5.1	2

108	SAT0561 Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 863.1-863	2.4	1
107	An overview of developing TNF- α -targeted therapy for the treatment of psoriasis. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1343-54	5.9	18
106	Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 594-603	4.5	143
105	Polymorphic blistering eruption and stomatitis in a patient with non-Hodgkin lymphoma. <i>JAMA Dermatology</i> , 2015 , 151, 439-40	5.1	2
104	Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 436-439.e1	4.5	39
103	Treatment of two patients with generalized pustular psoriasis with the interleukin-1 β inhibitor gevokizumab. <i>British Journal of Dermatology</i> , 2015 , 173, 239-41	4	44
102	Emerging oral drugs for psoriasis. <i>Expert Opinion on Emerging Drugs</i> , 2015 , 20, 209-20	3.7	15
101	OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 115-22	4.5	51
100	Research gaps in psoriasis: opportunities for future studies. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 146-67	4.5	85
99	Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 1183-1190.e3	4.5	88
98	Complementary data for long-term infliximab use in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 591	4.5	
97	The use of tumor necrosis factor inhibitors in pregnancy: what is the evidence?. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 829-31	4.5	0
96	Reply: To PMID 23317980. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 198	4.5	2
95	Angiolymphoid hyperplasia with eosinophilia. <i>Baylor University Medical Center Proceedings</i> , 2014 , 27, 336-7	0.6	6
94	The prevalence of Dupuytren contractures in patients with psoriasis. <i>Clinical and Experimental Dermatology</i> , 2014 , 39, 894-9	1.8	5
93	Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). <i>British Journal of Dermatology</i> , 2014 , 171, 137-47	4	89
92	Ponesimod--a future oral therapy for psoriasis?. <i>Lancet, The</i> , 2014 , 384, 2006-8	4.0	6
91	Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. <i>Biologics: Targets and Therapy</i> , 2014 , 8, 169-82	4.4	28

90 Recent and future developments in targeted therapy **2014**, 249-267

89	Polymorphic plaques involving the face and extremities. <i>JAMA Dermatology</i> , 2014 , 150, 643-4	5.1	0
88	Ustekinumab for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2014 , 10, 189-202	5.1	10
87	Reply: Genital edema in Crohn's disease. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 385	4.5	1
86	Recognizing and managing comorbidities and complications in hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014 , 33, S54-6	1.4	19
85	What you should know about hidradenitis suppurativa (HS): information for patients. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014 , 33, S60-1	1.4	
84	Hidradenitis suppurativa: update on diagnosis and treatment. Introduction. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014 , 33, S47	1.4	4
83	Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. <i>Journal of Drugs in Dermatology</i> , 2014 , 13, 554-62	2.2	20
82	Ustekinumab treatment for psoriasis in 119 patients maintained on therapy for a minimum of one year: a review. <i>Journal of Drugs in Dermatology</i> , 2014 , 13, 905-10	2.2	8
81	Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. <i>Journal of Drugs in Dermatology</i> , 2014 , 13, 1441-8	2.2	52
80	Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 634-42	4.6	39
79	Burden of disease: psoriasis and psoriatic arthritis. <i>American Journal of Clinical Dermatology</i> , 2013 , 14, 377-88	7.1	86
78	Biological therapies for psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1715-30	5.4	19
77	OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013 , 68, 756-64	4.5	26
76	Tumour necrosis factor- α inhibitor use in patients with psoriasis with organ transplantation. <i>British Journal of Dermatology</i> , 2013 , 169, 481-3	4	11
75	Emerging topical treatments for psoriasis. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 523-32	3.7	16
74	Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. <i>Journal of Drugs in Dermatology</i> , 2013 , 12, 92-8	2.2	29
73	Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. <i>British Journal of Dermatology</i> , 2012 , 167, 668-77	4	233

72	Current investigational drugs in psoriasis. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 473-87	5.9	27
71	Emerging therapies for the treatment of psoriasis. <i>Dermatology and Therapy</i> , 2012 , 2, 16	4	9
70	A subset of methylated CpG sites differentiate psoriatic from normal skin. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 583-92	4.3	104
69	Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 1349-61	4.5	35
68	Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. <i>New England Journal of Medicine</i> , 2012 , 366, 1181-9	59.2	755
67	Widespread dermal ulcerations and bullae. <i>Baylor University Medical Center Proceedings</i> , 2012 , 25, 155-8	0.6	
66	Secondary syphilis and HIV. <i>Baylor University Medical Center Proceedings</i> , 2012 , 25, 87-9	0.6	2
65	Psoriatic arthritis: an update. <i>Arthritis</i> , 2012 , 2012, 176298		35
64	Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis. <i>Cutis</i> , 2012 , 89, 89-94	0.4	2
63	Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 137-74	4.5	343
62	Use of pharmacogenomics in psoriasis. <i>Clinical Investigation</i> , 2011 , 1, 399-411		4
61	Letter from the editors. <i>Dermatology and Therapy</i> , 2011 , 1, 1	4	
60	Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 864-71	27.4	202
59	Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. <i>PLoS ONE</i> , 2011 , 6, e20279	3.7	41
58	Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review. <i>Journal of Drugs in Dermatology</i> , 2011 , 10, 539-44	2.2	12
57	OBSERVE-5, an Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis: A Model for Studying New Psoriasis Therapies. <i>Psoriasis Forum</i> , 2010 , 16a, 3-7		3
56	The International Psoriasis Council Presents Top 10 Psoriasis Research Articles for 2010. <i>Psoriasis Forum</i> , 2010 , 16a, 44-51		
55	Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. <i>New England Journal of Medicine</i> , 2010 , 362, 118-28	59.2	675

54	Goeckerman therapy versus biologics in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010 , 62, 516-7	4.5	2
53	The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. <i>Journal of the American Academy of Dermatology</i> , 2010 , 62, 812-8	4.5	121
52	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. <i>Journal of the American Academy of Dermatology</i> , 2010 , 62, 114-135	4.5	267
51	Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 448-56	4.5	115
50	The use of cyclosporine in dermatology: part II. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 949-72; quiz 973-4	4.5	72
49	The use of cyclosporine in dermatology: part I. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 925-46; quiz 947-8	4.5	110
48	Comorbidities in psoriasis patients. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010 , 29, 10-5	1.4	83
47	The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. <i>Molecular Diagnosis and Therapy</i> , 2010 , 14, 81-93	4.5	28
46	Pustules and dystrophy of the nails. <i>Baylor University Medical Center Proceedings</i> , 2009 , 22, 162-3	0.6	
45	Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. <i>Nature Genetics</i> , 2009 , 41, 199-204	36.3	1038
44	European S3-guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23 Suppl 2, 1-70	4.6	586
43	The ethics of consulting with pharmaceutical companies. <i>Clinics in Dermatology</i> , 2009 , 27, 339-45	3	2
42	Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 1024-31	4.5	80
41	Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 643-59	4.5	344
40	A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, S1-S46	4.5	28
39	Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, 451-85	4.5	427
38	Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet, The</i> , 2009 , 373, 633-40	4.0	476
37	The International Psoriasis Council Presents Top 2009 Research Articles. <i>Psoriasis Forum</i> , 2009 , 15a, 24-32		

36	Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. <i>Journal of Drugs in Dermatology</i> , 2009 , 8, 52-7	2.2	27
35	Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2008 , 159, 274-85	4	109
34	Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2008 , 159, 704-10	4	65
33	Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. <i>Health and Quality of Life Outcomes</i> , 2008 , 6, 75	3	34
32	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 106-15	4.5	685
31	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 826-50	4.5	958
30	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 851-64	4.5	349
29	Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. <i>Dermatology</i> , 2008 , 216, 260-70	4.4	97
28	Psoriasis as the marker of underlying systemic disease. <i>Skin Therapy Letter</i> , 2008 , 13, 1-5	1.8	4
27	One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses. <i>Cutis</i> , 2008 , 81, 509-16	0.4	10
26	Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. <i>Journal of Drugs in Dermatology</i> , 2008 , 7, 1137-46	2.2	12
25	Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2007 , 18, 341-50	2.8	72
24	Consistency of Infliximab Response across Subgroups of Patients with Psoriasis: Integrated Results from Randomized Clinical Trials. <i>Psoriasis Forum</i> , 2007 , 13a, 21-27		10
23	Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. <i>British Journal of Dermatology</i> , 2007 , 157, 649-55	4	236
22	Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. <i>International Journal of Dermatology</i> , 2007 , 46, 637-48	1.7	28
21	A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 31.e1-15	4.5	370
20	Current and future management of psoriasis. <i>Lancet, The</i> , 2007 , 370, 272-284	4.0	235
19	The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, 61-3	4.5	44

18	Long-term management of plaque psoriasis with continuous efalizumab therapy. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, S182-8	4.5	28
17	Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. <i>Archives of Dermatology</i> , 2005 , 141, 31-8		188
16	Cost-efficacy analysis of biological treatments in psoriasis: an 18-month assessment. <i>Journal of Medical Economics</i> , 2005 , 8, 139-146	2.4	4
15	Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. <i>British Journal of Dermatology</i> , 2005 , 152, 954-60	4	107
14	Biological therapies in the systemic management of psoriasis: International Consensus Conference. <i>British Journal of Dermatology</i> , 2004 , 151 Suppl 69, 3-17	4	139
13	The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004 , 8 Suppl 2, 20-5	1.6	9
12	A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, 859-66	4.5	205
11	Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2004 , 51, 534-42	4.5	464
10	Rationale for the use of topical corticosteroids in melasma. <i>Journal of Drugs in Dermatology</i> , 2004 , 3, 169-74	2.2	16
9	The Koo-Menter Psoriasis Instrument for Identifying Candidate Patients for Systemic Therapy. <i>Psoriasis Forum</i> , 2003 , 9a, 6-9		9
8	AAD consensus statement on psoriasis therapies. <i>Journal of the American Academy of Dermatology</i> , 2003 , 49, 897-9	4.5	91
7	The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. <i>Archives of Dermatology</i> , 2001 , 137, 280-4		564
6	Pathogenesis and genetics of psoriasis. <i>Cutis</i> , 1998 , 61, 8-10	0.4	4
5	Psoriasis symposium. Topical therapy. <i>Seminars in Dermatology</i> , 1992 , 11, 5-10		
4	Psoriasis symposium. Cyclosporine. <i>Seminars in Dermatology</i> , 1992 , 11, 30-4		
3	Psoriasis in practice. <i>Lancet, The</i> , 1991 , 338, 231-4	4.0	31
2	Recurrent renal cell carcinoma presenting as skin nodules: two case reports and review of the literature. <i>Cutis</i> , 1989 , 44, 305-8	0.4	17
1	Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab		5

